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Abstract
We aimed to compare post-transplantation morbidity and survival among heart transplant recipients with and without diabetes mellitus. A 
retrospective review of 141 adult patients submitted to heart transplantation from November 2003 to June 2009 (with a minimum follow-up 
of one year) was undertaken. The patients were divided into two groups: those with (29%) and those without (71%) pre-transplantation dia-
betes. Those with diabetes were older (57.6±6.1 vs. 52.3±11.1 years; P=0.020) and had lower creatinine clearance (53.6±15.1 vs. 63.7±22.1; 
P=0.029). Nine patients died in hospital (6.4%; P=non-significant). No significant differences in lipid profiles (diabetes vs. no diabetes) existed 
before transplantation or at one year afterwards. Patients with diabetes showed a significant deterioration in their one-year lipid profile 
(158±43 vs.192±38 mg/dL; P=0.001), although one-year fasting diabetic was lower than before (178±80 vs. 138±45 mg/dL; P=0.016). During 
the first year, 17 (17%) patients previously free of diabetes developed new-onset diabetes. No significant differences were seen in rejection 
at one year (14% vs. 20%), infection (31% vs. 33%), new-onset renal dysfunction (8% vs. 14%) or mortality (17% vs. 7%). One-year survival was 
not significantly different (83% vs. 94%), but there was a significant decrease in the survival of individuals with diabetes at three years (73% 
vs. 91%; P=0.020). No significant difference was found in one-year survival or in terms of higher morbidity in the heart transplant patients 
with diabetes, but a longer follow-up showed a significant decrease in survival. Nonetheless, the patients with diabetes benefited significantly 
from transplantation and should not be excluded from it.
© 2011 Published by European Association for Cardio-Thoracic Surgery. All rights reserved.
























The prevalence of diabetes mellitus is increasing world-
wide and is a significant risk factor for cardiovascular dis-
ease, which can manifest as coronary artery disease, heart 
failure, stroke and peripheral arterial disease, representing 
65% of all the deaths in the diabetic population [1].
Transplantation is now the gold standard for the treatment 
of end-stage heart failure, and the number of patients with 
diabetes is increasing. Some studies have highlighted an 
increased risk of infection post-transplant, rejection, coro-
nary artery disease, renal failure and mortality in diabetic 
recipients [2–4]. The International Society for Heart and 
Lung Transplantation (ISHLT) database shows an increase 
of 20–40% in late mortality among those with diabetes [5]. 
However, the results are sometimes contradictory, and 
some authors have found no differences in survival [3]. 
Recently, we reported no difference in survival at one year 
after transplantation [6].
On the other hand, immunosuppression aggravates pre-





















of new-onset diabetes [7]. Recent studies have shown that 
the incidence of new-onset diabetes after the first year of 
transplantation varies from 2% to 50% [6,8] and affects out-
comes. Hence, some centres have been reluctant to offer 
transplantation to patients with insulin-dependent diabetes.
Here, we intended to determine the morbidity and sur-
vival among heart transplant recipients with and without 
diabetes at our centre to try to understand how diabetes 
mellitus might affect late outcome.
2. Methods
2.1. Study protocol
Between November 2003 and June 2009, 141 patients 
over 18 years of age underwent first heart transplantation. 
Patients with diabetes mellitus without severe secondary 
end-organ disease [retinopathy, neuropathy or nephropathy 
with creatinine clearance (CrCl) <40 ml/min under opti-
mal medical therapy] [5], even with suboptimal glycaemic 
control, were included. The diagnosis of diabetes followed 
the American Diabetes Association criteria (fasting glucose 
≥126 mg/dl or two occasional measurements >200 mg/dl 
and symptoms of hyperglycaemia) [9].
The surgical technique employed was total transplanta-
tion with bicaval anastomoses. All patients underwent 




































J. Saraiva et al. / Interactive CardioVascular and Thoracic Surgery xx (2011) xxx-xxx








Male (%) 77 80 75 0.91
Age (years)±S.D. 53.6±10.6 57.6±6.1 52.3±11.1 0.020
Aetiology of heart failure (%)
 Dilated CM 56.7 48.8 60.0 0.62
 Ischaemic DCM 34.0 43.9 30.0 0.36
 Restrictive MC  8.5  7.3  9.0 0.97
 Others  0.7  0  1.0 0.64
Cardiovascular risk factors (%)
 Hypertension 16.3 24.4 13.0 0.25
 Dyslipidaemia 19.9 19.5 20.0 0.86
 Smoking 24.8 14.6 29.0 0.22
 Family history of coronary 
artery disease
12.1  9.8 13.0 0.85
 Body mass index (kg/m2)±S.D. 23.8±3.1 24.3±2.7 23.5±3.2 0.16
 Carotid disease 19.1 26.8 16.0 0.33
 Peripheral arterial disease 15.6 22.0 13.0 0.38
NYHA class (%)
 III 57.4 61.0 56.0 0.90
 IV 42.6 39.0 44.0 0.86
UNOS status (%)
 IA  6.7  9.8  4.0 0.39
 IB 17.0 17.1 17.0 0.82
 II 76.6 73.2 78.0 0.93
Sinus rhythm (%) 51.8 53.7 51.0 0.99
Atrial fibrillation (%) 20.6 19.5 21.0 0.95
Pacemaker rhythm (%) 22.7 12.2 27.0 0.18
aDiabetic vs. non-diabetic patients. Bold type represents statistical significance P<0.05. CM, cardiomyopathy; DCM, dilated cardiomyopathy; MC, myocardio-






























monoclonal receptor antibody (basiliximab) and mainte-
nance therapy mainly with cyclosporin (89% of patients) 
or tacrolimus, in association with mycophenolate mofetil 
and prednisone. All 132 patients who were discharged from 
hospital (94%) were medicated with a statin dose-adjusted 
to their lipid profile, and were highly incentivised to adopt 
personalised dietary and physical activity programmes.
For the purpose of this analysis, performed from a pro-
spectively organised database, the population was divided 
into two groups according to whether patients did or did not 
have pre-transplantation diabetes. All patients were fol-
lowed by a dedicated group of surgeons and cardio logists, 
applying internationally accepted consultation and myocar-
dial biopsy schedules. The follow-up was 100% complete 
and extended from 12 to 68 months.
The following complications were recorded: (1) mortality 
(cerebrovascular, cardiovascular, infection, rejection, post-
operative haemorrhage, and other); (2) severe infection; 
(3) malignancies; (4) renal dysfunction (creatinine >2 mg/dl); 
and (5) acute rejection (grade ≥2R of the ISHLT classifica-
tion of myocardial biopsy).
2.2. Statistical analysis
Continuous variables are presented as mean±standard devi-
ation (S.D.). Comparison between the two groups was made 
using the Student's unpaired t-test or the Mann–Whitney 
test, depending on whether or not the variables had a normal 
distribution. Categorical variables are expressed in percent-
ages and were analysed using the χ2-test or Fischer's exact 
test. Survival was analysed by the Kaplan–Meier method and 































used to test predetermined clinically important variables. A 
value of P<0.05 was considered statistically significant.
2.3. Baseline characteristics
The pre-transplantation demographic and general charac-
teristics of the patients are shown in Table 1. Forty-one of 
the 141 patients (29%) had diabetes mellitus, of whom 80% 
were medicated using various insulin regimens. The patients 
with diabetes were older, but there were no statistically sig-
nificant differences in the prevalence of cardiovascular risk 
factors or ischaemic heart failure between the two groups.
Table 2 shows the pre-transplant laboratory data. Diabetic 
patients more frequently presented a lower CrCl <60 ml/min 
(71% vs. 51% of those without diabetes) and significantly 
higher fasting plasma glucose levels. There were no signifi-
cant differences in the lipid profile, uric acid or C-reactive 
protein level, or pre-transplantation haemodynamic data 
between the groups (Table 3).
There were also no significant differences in relation to 
the characteristics of the donors (32±11 years, body mass 
index 24.9±3 kg/m2, and similar inotropic regimens). The 
mean time of myocardial ischaemia was 93.1±35.4 min, 
with no significant differences (96.5±38.0 for those with 
diabetes vs. 91.8±34.4 min for those without; P=0.99).
3. Results
3.1. New-onset diabetes
During the first year post-transplantation, 17 patients 














































LVEF (%)±S.D. 20.3±7.9 19.8±6.4 20.5±8.5 0.15
PSAP (mmHg)±S.D. 45.9±14.9 48.6±16.5 44.6±14.0 0.19
VO2 max (ml/min/kg)±S.D. 114±3.0 12.1±2.9 13.0±3.0 0.15
PVR (Wood units)±S.D. 2.7±1.2 2.6±1.1 2.7±1.3 0.64
Transpulmonary gradient (mmHg)±S.D. 8.5±4.4 9.8±4.8 8.0±4.1 0.053
aDiabetic vs. non-diabetic patients. LVEF, left ventricular ejection fraction; PSAP, systolic pulmonary artery pressure; PVR, pulmonary vascular resistance; S.D., 


















Fasting glucose (mg/dl)±S.D. 127±58 178±80 106±25 0.001
Creatinine clearance (mg/min)±S.D. 60.7±20.8 53.6±15.1 63.7±22.1 0.029
Total cholesterol (mg/dl)±S.D. 167±50 158±43 171±53 0.18
Low-density lipoprotein cholesterol (mg/dl)±S.D. 107±37.8 98±36.1 111±38.1 0.14
Triglycerides (mg/dl)±S.D. 111±52 115±60 109±49 0.78
Uricaemia (mg/dl)±S.D. 6.8±2.4 7.0±2.3 6.7±2.5 0.51
C-reactive protein±S.D. 1.3±1.9 1.2±1.8 1.3±1.9 0.12











158 mg/dl, P=0.001; low-density lipoprotein cholesterol 
118 mg/dl vs. 98 mg/dl, P=0.015). There was a signifi-
cant improvement in the control of fasting glucose level in 
patients with diabetes (glucose 178 mg/dl pre-transplant vs. 
138 mg/dl at follow-up; P=0.016). At one year post-trans-
plant, 17 patients without diabetes (17%) had developed 
new-onset diabetes (see below); hence 40% of the patients 
were diabetic, and 68% of these were on insulin regimens.
There were four additional deaths during the first year, 
for a total one-year mortality (including perioperative mor-
tality) of 9.2%, with no significant difference between the 
groups (17% in those with diabetes vs. 6.0% in those without; 
P=0.13), as shown in Fig. 1. Three of the late deaths were 
caused by infection. The survival at one-year follow-up 
was not significantly different (Fig. 2a), but at three years 
there was a significant decrease in the survival of diabetic 
patients (73% vs. 91%; P=0.020) (Fig. 2b). At five years, the 
difference was not significant (69% vs. 84%; P=0.29), prob-
ably due to the small size of the sample (Fig. 2c). Table 5
 shows the estimated survival (in days, ±S.D.) and 95% con-
fidence interval (CI) for individuals with and without dia-
betes at one, three and five years. There was no further 
evolution of the metabolic and haemodynamic profiles from 
those observed at one year.
Seven variables were tested to determine their influ-
ence on survival at one and five years: pre-transplantation 
diabetes (P=non-significant), pre-transplantation fasting 
glucose ≥126 mg/dl (P=non-significant), CrCl <60 ml/min 
(P=0.007 at one year; P=0.012 at five years), recipient's 
age >50 years (P=non-significant), donor's age >45 years 
(P=non-significant), status IA (P=0.048 at one year; P=non-
significant at five years) and total ischaemia time >90 min 
(P=non-significant). Using multivariate Cox regression anal-
ysis at one and five years, only CrCl <60 ml/min was a sig-




































the non-diabetic group. Pre-transplant fasting glucose 
impairment was observed in 26% of those who remained 
non-diabetic and in 53% (nine patients) of those who had 
developed new-onset diabetes by the one-year follow-up 
(P=0.22). Although not statistically significant, fasting glu-
cose impairment appeared to be a determining factor in the 
new onset of diabetes.
There was no significant difference in the immunosuppres-
sive regimen: 94% of those with diabetes received cyclo-
sporin, compared with 90% of those without (P=0.96). All 
patients who developed new-onset diabetes were initially 
medicated with cyclosporin. However, at one year there 
was a tendency for non-diabetic patients to have been 
changed to tacrolimus more often than those with diabetes 
(10.4% vs. 2.8%; P=0.34).
3.2. Clinical course
There was a significant difference in the mean time of post-
transplantation mechanical ventilation between patients 
with and without diabetes (23.6±47.2 h vs.16.9±16.6 h; 
P=0.017). There were nine hospital deaths (6.4%), as a 
result of hyperacute rejection, postoperative haemorrhage, 
cerebrovascular accidents and cardiovascular causes (two 
patients each) and one case of haemorrhagic pancreatitis, 
with no significant difference between those with and with-
out diabetes (12.2% vs. 4.0%; P=0.20). The mean hospital 
stay was 16.3±14.9 days (median 13 days), also with no sig-
nificant difference between the groups (15.9±9.7 for those 
with vs. 16.4±16.6 for those without diabetes; P=0.45).
With regards to the laboratory data (Table 4), there 
was no difference in the lipid profile between the two 
groups at one-year follow-up, but there was a significant 
deterioration in the diabetic group compared with the 
































































Fig. 1. Mortality and morbidity during the first year post-transplantation.
F1
F2
ratio of 9.7 (CI 95% 1.26–74.82) at one year and 9.0 (CI 95% 
1.12–72.03) at five years.
Forty-three patients (33%) had infectious episodes requir-
ing antimicrobial and/or antiviral therapy and close moni-
toring or hospitalisation [11 with diabetes (31%) vs. 32 
without (33%); P=0.98].
Fifty-two patients (39%) showed a deterioration in renal 
function during the first year after transplantation, but none 
required dialysis during this period; 16 of these patients 
(12%) had previously had normal renal function (8.3% of 
those with vs. 14% of those without diabetes, with initial 
CrCl ≥60 ml/min; P=0.67). However, at the three-year fol-
low-up, three patients with diabetes (4.9% of those alive) 
needed dialysis. None of the diabetic patients required 
dialysis. A total of 24 patients (18%) had had at least one 
episode of acute rejection ≥2R of the ISHLT classification 
(total number of episodes, 29), with no significant differ-
ence between groups (Fig. 1).
There were only three cases of post-transplant coro-
nary artery disease (TCAD) at one-year follow-up, one in 
a patient with diabetes and two in patients without. One 
of these had developed new-onset diabetes. When compar-
ing non-diabetic patients with patients with new-onset dia-
betes, there was no significant difference at the one-year 
follow-up (1.3% vs. 5.9%; P=0.34). No new cases of TCAD 
were detected up to the five-year follow-up.
At the five-year follow-up, there were 14 cases (11%) of 





























without; P=0.14). During the first year post-transplant, 
one non-diabetic patient developed a recurrent malig-
nant neurological tumour (0.7% of the total transplanted 
population).
4. Discussion
Diabetes mellitus is generally seen as a risk factor for and 
a complication of heart transplantation and immunosup-
pressive therapy, being considered by some to be at least 
a relative contraindication to transplantation [10]. In our 
centre, the percentage of diabetic patients among heart 
transplant recipients (29%) was higher than in many pub-
lished studies [3,4]. Nevertheless, the global survival at 
one-year follow-up (83%) was similar to that of patients 
without diabetes.
Neither fasting glucose impairment nor pre-transplantation 
diabetes were independent predictors of one-year mor-
tality [6]. This is in accordance with some other authors’ 
works, but differs from some studies with longer follow-up 
periods [2,11]. In fact, the three- and five-year mortalities 
observed in our study had already evolved to a lower sur-
vival in individuals with diabetes. We noticed no statisti-
cally significant differences in the incidences of infection, 
acute rejection or renal dysfunction during the first year, 
and this appeared to persist up to five years. In our centre, 
23% of deaths at the one-year follow-up were due to infec-



































Fasting glucose (mg/dl)±S.D. 114±37 138±45 104±28 0.001
Total cholesterol (mg/dl)±S.D. 202±45 192±38 205±47 0.14
Low-density lipoprotein cholesterol (mg/dl)±S.D. 128±40 118±29 132±43 0.17
Triacylglycerol (mg/dl)±S.D. 169±81 175±69 166±86 0.25
Uricaemia (mg/dl)±S.D. 7.0±2.0 6.8±1.9 7.1±2.1 0.72



















Table 5. Estimate of survival (days±S.D.) of patients with and without diabe-
tes and 95% confidence intervals (CI) at one, three and five years
Condition Estimate of survival 
time (days)±S.D.
95% CI P-valuea
One year Diabetic  317.8±17.9  282.7–352.8 0.065
Non-diabetic  342.5±78.3  326.3–358.7
Three years Diabetic  901.3±67.2  769.5–1033.0 0.020
Non-diabetic 1021.7±31.2  960.4–1082.9
Five years Diabetic 1422.8±172.3 1085.1–1760.6 0.29
Non-diabetic 1616.2±95.3 1429.5–1802.9










































































Fig. 2. (a) One-year survival of heart transplant recipients with (n=41) vs. 
without (n=100) diabetes (P=0.065). (b) Three-year survival of patients 
with (n=30) vs. without (n=67) diabetes (P=0.020). (c) Five-year survival of 






and without diabetes. The same was true for death due 
to cardiovascular causes (23%), acute rejection, haemor-
rhage and cardiovascular or cerebrovascular causes (15% 
each). By contrast, renal insufficiency (CrCl <60 ml/min) 
was confirmed as a significant predictor of one-year mor-
tality (hazard ratio 9.7, 95% CI 1.26–74.82; P=0.029) and 
five-year mortality (hazard ratio 9.0, 95% CI 1.12–72.03; 
P=0.039).
The incidence of new-onset diabetes in our population was 
17%, lower than that reported in other studies. It is known 
that immunosuppressors, especially the calcineurin inhibi-
tors and steroids, play an important role in the develop-
ment of diabetes. Tacrolimus is known to have a five-times 
higher diabetogenic effect than cyclosporin [4], and 18% of 
our non-diabetic patients who were changed to tacrolimus 
developed new-onset diabetes.
Our lower incidence of new-onset diabetes may also be 
explained by individualised therapeutic regimens and the 
aggressive metabolic control programme. It has previously 
been demonstrated that lipid-lowering agents, such as 
statins, raise the sensitivity to insulin and reduce the risk 
of new-onset diabetes after heart transplantation [12]. In 
addition, the use of drugs with known cardiovascular- and 
diabetes-protective properties, like angiotensin-converting 
enzyme inhibitors, which help to decrease insulin resis-
tance [13,14], contributes to preventing new-onset diabe-
tes and to delaying the metabolic effects of already present 
diabetes. However, oral glucose tolerance and haemoglobin 
A1c level were not routinely tested at our centre, so the 
percentage of new-onset diabetes may be underestimated. 
Nevertheless, we observed a significant improvement in the 
control of fasting glucose levels in patients with diabetes at 
the one-year follow-up.
Finally, there was no difference between the lipid pro-
files of patients with and without diabetes, although we 
noticed a significant deterioration in the lipid profile 
of the diabetic group. Hence, we may say that having 
diabetes does not necessary raise the risk of complica-
tions associated with the lipid profile in the long-term. 
Additionally, 68% of diabetic patients were medicated 
with insulin regimens after heart transplantation, which 
makes it difficult to obtain long fasting periods; there-
fore, the assessment of lipid profile may be suboptimal 
in some patients.
This study has obvious shortcomings. The small size of our 
population and the short period of follow-up recommend 
caution in deriving conclusions and statistical significances. 
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Conference discussion
Dr. S. Daebritz (Dusseldorf, Germany): This interesting talk touches on 
the increasingly discussed issue of prioritising limited medical treatment for 
specific patients. According to the ISHLT Registry, about 20% of heart recipi-
ents are diabetic. 
May I ask you for three comments: The mortality in follow-up is attributed 
to the comorbidity of diabetes potentiated by the side effects of immunosup-
pression. Did you coincidentally look at the time period the patients were 
insulin-dependent prior to transplantation, which the registries can’t look 
at, just to see whether there is an impact of subclinical preexisting micro-
vascular damage on outcome?
And second, did you have a specific regimen for the use of statins and 
control of the lipid profile and hypertension and weight in these patients?
And third, most importantly, did you apply a specific immunosuppressive 
protocol to these patients, particularly with regard to steroids? We had about 
more than 95% of patients steroid-free one year after transplantation, and 
this has proven to be beneficial, particularly for diabetic patients. 
Dr Saraiva: Regarding the first question, some diabetics presented for 
transplant with a recent diagnosis of diabetes and so they were on insulin for 
a short time. So it’s hard to say if they were on insulin for one year or just 
one month. We have some information on whether they were on insulin or 
oral antidiabetics, but we did not analyse that data. 
About the second question, all the patients discharged from hospital were 
medicated initially with pravastatin, 20 mg, and then the statins were 
adjusted to the lipid profile of the patient. We insist on a rigorous diet and 
exercise program and medications, including statins, to control the lipid pro-
file and to improve the glycaemic profile of diabetics. 
As to the third question, the diabetic patients constitute a special thera-
peutic problem. So we adjust all the immunosuppressors individually. We try 
to avoid using tacrolimus initially in diabetic patients, because we know that 
it has a hyperglycaemic effect about five times greater than cyclosporine. 
We also try to reduce the steroids as soon as possible without compromising 





























































better define the impact of diabetes mellitus in heart trans-
plantation programmes.
5. Conclusion
In conclusion, no significant difference was seen in the 
prognosis of those with diabetes during the first year after 
heart transplantation, as long as patients maintained tight 
glucometabolic control. However, at three-year follow-
up, survivals were significantly inferior among diabetic 
patients, although there were no significant differences 
in late morbidity. Preoperative fasting glucose impairment 
appears to raise the risk of development of new-onset 
diabetes after transplantation. Renal insufficiency was a 
predictor of one- and five-year mortality; hence, it is cru-
cial to maintain a tight control and optimisation of renal 
function.
We believe that, overall, the results of heart transplan-
tation in patients with diabetes mellitus are good, so this 
group should not be denied transplantation, although they 
require tighter glucometabolic control with individualised 
therapeutic regimens and lifestyle adjustments.
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